NatureWise Biotech & Medicals Corporation (4732.TWO) Stock
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It also sells food and beverages.
Valuation
Financials & Margins
Valuation & Return Ratios
About NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It also sells food and beverages. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
NatureWise Biotech & Medicals Corporation is led by CEO Zhong Yang Huang, employs 32 people, headquartered in Taipei, TW, publicly traded since 2007.
NatureWise Biotech & Medicals Corporation (4732.TWO) stock trades at $16.35 with a market capitalization of $792.26M. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.23, reflecting a net loss over the last twelve months, price-to-book of 1.42, price-to-sales of 4.54. Over the past 52 weeks the stock has ranged between $15.25 and $24.60, and currently trades 33.5% below its 52-week high.
On profitability, NatureWise Biotech & Medicals Corporation generates a return on equity (ROE) of -26.83% (negative, reflecting a net loss), an operating margin of -106.36%, a net profit margin of -76.55%.
Official website: www.naturewise.com.tw
NatureWise Biotech & Medicals Corporation (4732.TWO) — frequently asked questions
What is NatureWise Biotech & Medicals Corporation (4732.TWO) stock price today?
NatureWise Biotech & Medicals Corporation (4732.TWO) is currently trading at $16.35, down 2.97% today.
What is 4732.TWO P/E ratio?
NatureWise Biotech & Medicals Corporation's P/E ratio is -6.23. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is 4732.TWO return on equity (ROE)?
NatureWise Biotech & Medicals Corporation's return on equity (ROE) is -26.83%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is NatureWise Biotech & Medicals Corporation's market cap?
NatureWise Biotech & Medicals Corporation has a market capitalization of $792.26M.
Does 4732.TWO pay a dividend?
NatureWise Biotech & Medicals Corporation is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 4732.TWO carry?
NatureWise Biotech & Medicals Corporation has a debt-to-equity ratio of 0.05. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 4732.TWO's profit margin?
NatureWise Biotech & Medicals Corporation reports a net profit margin of -76.55% — the share of revenue left after every cost, including tax and interest.
What sector is 4732.TWO in?
NatureWise Biotech & Medicals Corporation is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 4732.TWO listed on?
NatureWise Biotech & Medicals Corporation trades on TWO under the ticker 4732.TWO.
What is 4732.TWO's 52-week range?
Over the last year NatureWise Biotech & Medicals Corporation has traded between $15.25 and $24.60.
Related Healthcare Stocks
Popular Stocks
Screens 4732.TWO currently matches
On the figures above, NatureWise Biotech & Medicals Corporation passes the filters for 5 of our ready-made screens, among them Small Cap Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.